Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7QJU

EED in complex with PRC2 allosteric inhibitor compound 7

7QJU の概要
エントリーDOI10.2210/pdb7qju/pdb
関連するPDBエントリー7QJG
分子名称Polycomb protein EED, Histone-lysine N-methyltransferase EZH2, CHLORIDE ION, ... (5 entities in total)
機能のキーワードinhibitor, complex, transferase
由来する生物種Homo sapiens (human)
詳細
タンパク質・核酸の鎖数4
化学式量合計92641.23
構造登録者
Zhao, K.,Zhao, M.,Luo, X.,Zhang, H.,Scheufler, C. (登録日: 2021-12-17, 公開日: 2022-04-13, 最終更新日: 2024-11-13)
主引用文献Huang, Y.,Sendzik, M.,Zhang, J.,Gao, Z.,Sun, Y.,Wang, L.,Gu, J.,Zhao, K.,Yu, Z.,Zhang, L.,Zhang, Q.,Blanz, J.,Chen, Z.,Dubost, V.,Fang, D.,Feng, L.,Fu, X.,Kiffe, M.,Li, L.,Luo, F.,Luo, X.,Mi, Y.,Mistry, P.,Pearson, D.,Piaia, A.,Scheufler, C.,Terranova, R.,Weiss, A.,Zeng, J.,Zhang, H.,Zhang, J.,Zhao, M.,Dillon, M.P.,Jeay, S.,Qi, W.,Moggs, J.,Pissot-Soldermann, C.,Li, E.,Atadja, P.,Lingel, A.,Oyang, C.
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.
J.Med.Chem., 65:5317-5333, 2022
Cited by
PubMed Abstract: Polycomb Repressive Complex 2 (PRC2) plays an important role in transcriptional regulation during animal development and in cell differentiation, and alteration of PRC2 activity has been associated with cancer. On a molecular level, PRC2 catalyzes methylation of histone H3 lysine 27 (H3K27), resulting in mono-, di-, or trimethylated forms of H3K27, of which the trimethylated form H3K27me3 leads to transcriptional repression of polycomb target genes. Previously, we have shown that binding of the low-molecular-weight compound EED226 to the H3K27me3 binding pocket of the regulatory subunit EED can effectively inhibit PRC2 activity in cells and reduce tumor growth in mouse xenograft models. Here, we report the stepwise optimization of the tool compound EED226 toward the potent and selective EED inhibitor MAK683 (compound ) and its subsequent preclinical characterization. Based on a balanced PK/PD profile, efficacy, and mitigated risk of forming reactive metabolites, MAK683 has been selected for clinical development.
PubMed: 35352560
DOI: 10.1021/acs.jmedchem.1c02148
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.8 Å)
構造検証レポート
Validation report summary of 7qju
検証レポート(詳細版)ダウンロードをダウンロード

252816

件を2026-04-29に公開中

PDB statisticsPDBj update infoContact PDBjnumon